Transplant News and Research

RSS

Practical guidance for cardiothoracic transplant programs in view of H1N1 flu pandemic

Each year 3-5 million people have severe cases and 250-500,000 die from complications of seasonal influenza world-wide. This year, the novel 2009 H1N1 (nH1N1) influenza, previously called swine flu, has reached pandemic status.

23 Oct 2009

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Biotech company Pharming Group NV announced today publication of a preclinical study showing the benefit of using recombinant human C1 inhibitor (rhC1INH) in ischemic brain injury.

23 Oct 2009

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter ended September 30, 2009.

22 Oct 2009

The Sutter Heart Transplant Program gets recertified after an eight-month legal battle

Larry Clymer's heart was just plum wearing out. The 60-year-old Rocklin resident needed a heart transplant, and a temporary machine was implanted in his abdomen to keep his heart beating until the right heart was identified.

22 Oct 2009

VisionGraft Sterile Cornea allograft now available at Tissue Banks International

Tissue Banks International (TBI) has announced the availability of the VisionGraft Sterile Cornea, the nation's first sterile cornea allograft. The VisionGraft Sterile Cornea (patent pending) is an irradiated cornea for use in tectonic transplant procedures.

22 Oct 2009

VeriChip collaborates with DRI for further development of the glucose-sensing RFID microchip

VeriChip Corporation announced today that it has entered into a strategic partnership with the Diabetes Research Institute ("DRI") to combine efforts on the further development of the glucose-sensing radio frequency identification (RFID) microchip in conjunction with VeriChip's development partner, RECEPTORS LLC.

22 Oct 2009

NIH awards $8 million to The Medical College of Wisconsin for heart research

The Medical College of Wisconsin has been awarded a five-year, $8 million, multi-investigator Program Project Grant (PPG) from the National Institutes of Health to understand how human pluripotent stem cells, defined as cells which if left to their own designs can develop into any of the more than 200 cell types in the human body, can be channeled to exclusively become heart muscle cells.

22 Oct 2009

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Gamida Cell Ltd. and Cellerix, S.A. announced today that the companies are collaborating on a feasibility study to evaluate the added value of combining the proprietary technologies of each.

21 Oct 2009

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.

21 Oct 2009

Genzyme commences patient enrollment in Genz-112638 phase 3 trials

Genzyme Corporation today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.

21 Oct 2009

Venture capital competition: MicroMed Cardiovascular in Top 50 Emerging Companies list

On Oct. 8, MicroMed Cardiovascular (www.micromedcv.com), manufacturer of the HeartAssist 5™ left ventricular assist device (LVAD), was selected as one of the Top 50 Emerging Companies in the nation’s largest venture capital competition, the Sixth Annual Pitching Across America competition.

21 Oct 2009

Retinal prosthesis restores partial vision to people who are totally blind

Two experimental treatments, a retinal prosthesis and fetal tissue transplant, restored some vision to people with blinding eye diseases. The findings, presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health, may lead to new treatments for the blind. Researchers also reported that an engineered protein restored vision in an animal model and identified ways to improve stem cell treatments.

21 Oct 2009

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Most Canadians living with CKD have likely never spoken with their physicians about calcium and the serious health risks associated with its overuse. This is why Improving Patient Advocacy in Chronic Kidney Disease (ImPACKD), a group of CKD patients and caregivers committed to raising awareness about the risks of calcium overuse, is starting the conversation about the importance of knowing the limits and keeping them in check.

20 Oct 2009

NCCN Guidelines for Acute Myeloid Leukemia updated

The National Comprehensive Cancer Network (NCCN) recently made updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Acute Myeloid Leukemia, a cancer that starts inside the bone marrow and the most common acute leukemia affecting adults.

20 Oct 2009

Cangene to acquire U.S. commercialization rights for HepaGam B

Cangene Corporation today announces that it has signed an agreement with its majority shareholder, the Apotex Group, under which Cangene acquires all U.S. commercialization rights for HepaGam B(R) (Hepatitis B Immune Globulin Intravenous (Human)). HepaGam B(R) is Cangene's hepatitis B immune globulin, which is approved for treating two hepatitis-B-related indications in the U.S.

20 Oct 2009

Optimer Pharmaceuticals to present additional data on fidaxomicin at the 47th IDSA meeting

Optimer Pharmaceuticals, Inc. announced that additional data related to fidaxomicin, the Company's lead developmental product candidate for the treatment of Clostridium difficile infection, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) to be held at The Philadelphia Convention Center in Philadelphia, Pennsylvania October 29 through November 1, 2009.

20 Oct 2009

New technique to treat metabolic disorders in babies while still in the womb

Researchers say a new development in cord blood transplants for inherited metabolic disorders may be curative for some babies who are treated while still in the womb.

20 Oct 2009

Article evaluating StemEx therapy for leukemia and lymphoma to be published

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.

19 Oct 2009

Is 'model health system' Geisinger replicable elsewhere?

Geisinger Health System, in central Pennsylvania, has been widely hailed as a model for health reform by leading Democrats including President Obama, the Philadelphia Inquirer reports. But, its success may hinge on "a rare combination of factors" including "a relative lack of competition, its stable patient base, and the fact that its 800 doctors are on salary," as well as an in-house pharmacy and insurance plan that covers one-third of its patients.

19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Transplant News and Research

Practical guidance for cardiothoracic transplant programs in view of H1N1 flu pandemic

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

The Sutter Heart Transplant Program gets recertified after an eight-month legal battle

VisionGraft Sterile Cornea allograft now available at Tissue Banks International

VeriChip collaborates with DRI for further development of the glucose-sensing RFID microchip

NIH awards $8 million to The Medical College of Wisconsin for heart research

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year

Genzyme commences patient enrollment in Genz-112638 phase 3 trials

Venture capital competition: MicroMed Cardiovascular in Top 50 Emerging Companies list

Retinal prosthesis restores partial vision to people who are totally blind

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

NCCN Guidelines for Acute Myeloid Leukemia updated

Cangene to acquire U.S. commercialization rights for HepaGam B

Optimer Pharmaceuticals to present additional data on fidaxomicin at the 47th IDSA meeting

New technique to treat metabolic disorders in babies while still in the womb

Article evaluating StemEx therapy for leukemia and lymphoma to be published

Is 'model health system' Geisinger replicable elsewhere?

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Industry Focus eBook - Cell biology (5th edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News